Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 2
1978 1
1980 1
1985 1
1986 1
1987 1
1989 2
1990 1
1991 1
1992 4
1994 2
1996 1
1997 4
1998 2
1999 4
2000 2
2001 1
2002 33
2003 66
2004 71
2005 72
2006 113
2007 132
2008 186
2009 198
2010 248
2011 290
2012 331
2013 354
2014 448
2015 507
2016 587
2017 637
2018 730
2019 728
2020 909
2021 1053
2022 1217
2023 1141
2024 1045
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9,907 results

Results by year

Filters applied: . Clear all
Page 1
Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis.
Wang X, Wu X, Tan B, Zhu L, Zhang Y, Lin L, Xiao Y, Sun A, Wan X, Liu S, Liu Y, Ta N, Zhang H, Song J, Li T, Zhou L, Yin J, Ye L, Lu H, Hong J, Cheng H, Wang P, Li W, Chen J, Zhang J, Luo J, Huang M, Guo L, Pan X, Jin Y, Ye W, Dai L, Zhu J, Sun L, Zheng B, Li D, He Y, Liu M, Wu H, Du B, Xu H. Wang X, et al. Among authors: lin l. Cell. 2024 Sep 5;187(18):4890-4904.e9. doi: 10.1016/j.cell.2024.06.027. Epub 2024 Jul 15. Cell. 2024. PMID: 39013470
FGF9 Recruits β-Catenin to Increase Hepatic ECM Synthesis and Promote NASH-Driven HCC.
Zhang L, Zhang Q, Teng D, Guo M, Tang K, Wang Z, Wei X, Lin L, Zhang X, Wang X, Huang D, Ren C, Yang Q, Zhang W, Gao Y, Chen W, Chang Y, Zhang H. Zhang L, et al. Among authors: lin l. Adv Sci (Weinh). 2023 Oct;10(28):e2301166. doi: 10.1002/advs.202301166. Epub 2023 Aug 11. Adv Sci (Weinh). 2023. PMID: 37566761 Free PMC article.
Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia.
Lo MY, Tsai XC, Lin CC, Tien FM, Kuo YY, Lee WH, Peng YL, Liu MC, Tseng MH, Hsu CA, Chen JC, Lin LI, Sun HI, Chuang YK, Ko BS, Tang JL, Yao M, Chou WC, Hou HA, Tien HF. Lo MY, et al. Among authors: lin li. Am J Hematol. 2023 May;98(5):760-769. doi: 10.1002/ajh.26892. Epub 2023 Mar 13. Am J Hematol. 2023. PMID: 36861732 Free article.
Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial.
Sun Y, Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, Sun Y, Chen XZ, Li JG, Zhu XD, Hu CS, Xu XY, Chen YY, Hu WH, Guo L, Mo HY, Chen L, Mao YP, Sun R, Ai P, Liang SB, Long GX, Zheng BM, Feng XL, Gong XC, Li L, Shen CY, Xu JY, Guo Y, Chen YM, Zhang F, Lin L, Tang LL, Liu MZ, Ma J. Sun Y, et al. Among authors: lin l. Lancet Oncol. 2016 Nov;17(11):1509-1520. doi: 10.1016/S1470-2045(16)30410-7. Epub 2016 Sep 27. Lancet Oncol. 2016. PMID: 27686945 Clinical Trial.
Noncanonical regulation of HOIL-1 on cancer stemness and sorafenib resistance identifies pixantrone as a novel therapeutic agent for HCC.
Chen P, Dong Z, Zhu W, Chen J, Zhou Y, Ye Q, Liao X, Tan Y, Li C, Wang Y, Pang H, Wen C, Jiang Y, Li X, Li B, Aimaier A, Lin L, Sun J, Hou J, Tang L, Hou J, Li Y. Chen P, et al. Among authors: lin l. Hepatology. 2024 Aug 1;80(2):330-345. doi: 10.1097/HEP.0000000000000623. Epub 2023 Oct 11. Hepatology. 2024. PMID: 37820061
9,907 results